PMID- 28120419
OWN - NLM
STAT- MEDLINE
DCOM- 20170717
LR  - 20220311
IS  - 1096-8652 (Electronic)
IS  - 0361-8609 (Linking)
VI  - 92
IP  - 4
DP  - 2017 Apr
TI  - Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers 
      (IGHV mutational status and FISH cytogenetics) separates patients with different 
      outcome and simplifies the CLL-IPI.
PG  - 375-380
LID - 10.1002/ajh.24660 [doi]
AB  - Rai and Binet staging systems are important to predict the outcome of patients 
      with chronic lymphocytic leukemia (CLL) but do not reflect the biologic diversity 
      of the disease nor predict response to therapy, which ultimately shape patients' 
      outcome. We devised a biomarkers-only CLL prognostic system based on the two most 
      important prognostic parameters in CLL (i.e., IGHV mutational status and 
      fluorescence in situ hybridization [FISH] cytogenetics), separating three 
      different risk groups: (1) low-risk (mutated IGHV + no adverse FISH cytogenetics 
      [del(17p), del(11q)]); (2) intermediate-risk (either unmutated IGHV or adverse 
      FISH cytogenetics) and (3) high-risk (unmutated IGHV + adverse FISH 
      cytogenetics). In 524 unselected subjects with CLL, the 10-year overall survival 
      was 82% (95% CI 76%-88%), 52% (45%-62%), and 27% (17%-42%) for the low-, 
      intermediate-, and high-risk groups, respectively. Patients with low-risk 
      comprised around 50% of the series and had a life expectancy comparable to the 
      general population. The prognostic model was fully validated in two independent 
      cohorts, including 417 patients representative of general CLL population and 337 
      patients with Binet stage A CLL. The model had a similar discriminatory value as 
      the CLL-IPI. Moreover, it applied to all patients with CLL independently of age, 
      and separated patients with different risk within Rai or Binet clinical stages. 
      The biomarkers-only CLL prognostic system presented here simplifies the CLL-IPI 
      and could be useful in daily practice and to stratify patients in clinical 
      trials.
CI  - (c) 2017 Wiley Periodicals, Inc.
FAU - Delgado, Julio
AU  - Delgado J
AD  - Department of Hematology, Institute of Hematology and Oncology, Hospital Clinic, 
      IDIBAPS, University of Barcelona, Barcelona, Spain.
FAU - Doubek, Michael
AU  - Doubek M
AD  - Department of Internal Medicine - Hematology and Oncology, University Hospital 
      Brno and Medical Faculty, Brno, Czech Republic.
AD  - Central European Institute of Technology (CEITEC), Masaryk University, Brno, 
      Czech Republic.
FAU - Baumann, Tycho
AU  - Baumann T
AD  - Department of Hematology, Institute of Hematology and Oncology, Hospital Clinic, 
      IDIBAPS, University of Barcelona, Barcelona, Spain.
FAU - Kotaskova, Jana
AU  - Kotaskova J
AD  - Department of Internal Medicine - Hematology and Oncology, University Hospital 
      Brno and Medical Faculty, Brno, Czech Republic.
AD  - Central European Institute of Technology (CEITEC), Masaryk University, Brno, 
      Czech Republic.
FAU - Molica, Stefano
AU  - Molica S
AD  - Department Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, 
      Italy.
FAU - Mozas, Pablo
AU  - Mozas P
AD  - Department of Hematology, Institute of Hematology and Oncology, Hospital Clinic, 
      IDIBAPS, University of Barcelona, Barcelona, Spain.
FAU - Rivas-Delgado, Alfredo
AU  - Rivas-Delgado A
AD  - Department of Hematology, Institute of Hematology and Oncology, Hospital Clinic, 
      IDIBAPS, University of Barcelona, Barcelona, Spain.
FAU - Morabito, Fortunato
AU  - Morabito F
AD  - UOC Ematologia, Azienda Ospedaliera di Cosenza, Cosenza, Italy.
FAU - Pospisilova, Sarka
AU  - Pospisilova S
AD  - Department of Internal Medicine - Hematology and Oncology, University Hospital 
      Brno and Medical Faculty, Brno, Czech Republic.
AD  - Central European Institute of Technology (CEITEC), Masaryk University, Brno, 
      Czech Republic.
FAU - Montserrat, Emili
AU  - Montserrat E
AUID- ORCID: 0000-0002-2868-995X
AD  - Department of Hematology, Institute of Hematology and Oncology, Hospital Clinic, 
      IDIBAPS, University of Barcelona, Barcelona, Spain.
LA  - eng
PT  - Journal Article
PT  - Validation Study
DEP - 20170213
PL  - United States
TA  - Am J Hematol
JT  - American journal of hematology
JID - 7610369
RN  - 0 (Biomarkers)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers/analysis
MH  - Cohort Studies
MH  - Genes, Immunoglobulin Heavy Chain
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*diagnosis/mortality
MH  - Middle Aged
MH  - Mutation
MH  - Prognosis
MH  - Risk Assessment
MH  - Survival Rate
MH  - Young Adult
EDAT- 2017/01/26 06:00
MHDA- 2017/07/18 06:00
CRDT- 2017/01/26 06:00
PHST- 2017/01/10 00:00 [received]
PHST- 2017/01/17 00:00 [revised]
PHST- 2017/01/20 00:00 [accepted]
PHST- 2017/01/26 06:00 [pubmed]
PHST- 2017/07/18 06:00 [medline]
PHST- 2017/01/26 06:00 [entrez]
AID - 10.1002/ajh.24660 [doi]
PST - ppublish
SO  - Am J Hematol. 2017 Apr;92(4):375-380. doi: 10.1002/ajh.24660. Epub 2017 Feb 13.